The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A Compressive Review about Taxol®: History and Future Challenges
Open accessAbstract
Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over one million patients, making it one of the most widely employed antitumoral drugs. Taxol® was the first microtubule targeting agent described in the literature, with its main mechanism of action consisting of the disruption of microtubule dynamics, thus inducing mitotic arrest and cell death. However, secondary mechanisms for achieving apoptosis have also been demonstrated. Despite its wide use, Taxol® has certain disadvantages. The main challenges facing Taxol® are the need to find an environmentally sustainable production method based on the use of microorganisms, increase its bioavailability without exerting adverse effects on the health of patients and minimize the resistance presented by a high percentage of cells treated with paclitaxel. This review details, in a succinct manner, the main aspects of this important drug, from its discovery to the present day. We highlight the main challenges that must be faced in the coming years, in order to increase the effectiveness of Taxol® as an anticancer agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multilayered complexity of ceRNA crosstalk and competition
Tay, Y., Rinn, J., & Pandolfi, P. P. (2014) · Nature · doi:10.1038/nature12986 · Cited by 3,910
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Rohmer, M., Seemann, M., Horbach, S., Bringer-Meyer, S., & Sahm, H. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9538344 · Cited by 484
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.289 · Cited by 133
Autophagy role(s) in response to oncogenes and DNA replication stress
Vanzo, R., Bartkova, J., Merchut-Maya, J. M., Hall, A., Bouchal, J., Dyrskjøt, L., Frankel, L. B., Gorgoulis, V., Maya-Mendoza, A., Jäättelä, M., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0403-9 · Cited by 79
Cited by
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
Zhang, C., Chen, W., Dong, T., Wang, Y., Yao, M., Xiao, W., & Li, B. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1141272 · Cited by 16
Microtubule lattice state regulates Rho GTPase
Al-Bassam, J., & Ashaduzzaman, M. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-02111-7
Metadata
- Authors
- Gallego-Jara, J., Lozano-Terol, G., Sola-Martínez, R. A., Cánovas-Díaz, M., & de Diego Puente, T.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-17
- Volume
- 25
- Issue
- 24
- Pages
- 5986
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3110830766
- Cited by
- 344
- References
- 8
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Compressive Review about Taxol®: History and Future Challenges. https://app.cochat.ai/papers/10.3390/molecules25245986
- The paper
- Gallego-Jara, J., Lozano-Terol, G., Sola-Martínez, R. A., Cánovas-Díaz, M., & de Diego Puente, T. (2020). A Compressive Review about Taxol®: History and Future Challenges. Molecules. https://doi.org/10.3390/molecules25245986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
